The Hidden Distortion: How Pregnancy Alters Your A1c and What to Do About It

Gestational diabetes mellitus (GDM) affects up to 10% of pregnancies worldwide, presenting significant risks to both maternal and fetal health if not properly managed. The cornerstone of diabetes care outside of pregnancy is the hemoglobin A1c test, which provides a three-month average of blood glucose levels. However, the profound physiological shifts that occur during gestation can distort A1c readings, leading to misdiagnosis or suboptimal glucose control. Understanding these distortions is not a niche concern—it is essential for every clinician caring for pregnant individuals. This article explores the mechanisms behind pregnancy-related A1c inaccuracies, the limitations they impose, and the evidence-based alternative monitoring strategies that ensure safe, effective care for both mother and child.

What Is A1c and How Does It Work?

The A1c test, also known as glycated hemoglobin, measures the percentage of hemoglobin in red blood cells (RBCs) that has glucose bound to its beta-chain N-terminal valine. This binding is irreversible and occurs continuously over the 120-day lifespan of a typical RBC. Because glucose enters RBCs passively and is trapped when attached to hemoglobin, the A1c value reflects the mean glycemia experienced by those cells over their lifetime, weighted toward the most recent 30 days.

In non-pregnant adults, an A1c of 5.7% to 6.4% indicates prediabetes, while 6.5% or higher confirms diabetes. For individuals with established diabetes, the American Diabetes Association (ADA) recommends an A1c target below 7% to reduce microvascular complications. The test's convenience—no fasting required, single blood draw, and stable sample—has made it the gold standard for long-term glycemic assessment. Yet, the very mechanisms that make A1c reliable in non-pregnant adults are precisely what break down during pregnancy, as we will examine in depth.

Physiological Changes During Pregnancy That Alter A1c Accuracy

Pregnancy induces a cascade of hematologic and metabolic alterations that directly affect the A1c measurement. These changes render the standard interpretation of A1c unreliable and can lead to significant clinical errors if not fully understood.

1. Expansion of Plasma Volume and Hemodilution

By the third trimester, maternal blood volume increases by approximately 40–50% to support the growing uteroplacental unit. This dramatic hemodilution lowers the concentration of hemoglobin and other plasma proteins. Since A1c is reported as a percentage of total hemoglobin, a lower total hemoglobin concentration can artificially depress the A1c result even when absolute glycated hemoglobin remains unchanged. Studies show that this dilution effect can reduce A1c by 0.3–0.5% compared to non-pregnant values at the same glucose levels. For a woman with true mean glucose of 180 mg/dL, this dilution could drop her A1c from approximately 7.8% to the 7.3–7.5% range—pushing her below a treatment target and creating a false sense of security.

2. Accelerated Red Blood Cell Turnover

During normal pregnancy, RBC lifespan decreases from 120 days to approximately 90–100 days due to increased erythropoietin production and mechanical stress from expanded blood volume. Shorter-lived RBCs spend less time exposed to circulating glucose, resulting in less glycation per cell. The younger the average RBC population, the lower the A1c reading for any given ambient glucose concentration. This effect can produce A1c values that severely underestimate true glycemic status. Research indicates that this shortened lifespan alone can lower A1c by an additional 0.2–0.4%, compounding the dilution effect for a total potential suppression of 0.5–0.9% compared to non-pregnant physiology.

3. Iron Deficiency and Anemia

Iron deficiency anemia is prevalent in pregnancy, affecting up to 30% of women globally. Iron deficiency alters the structure of hemoglobin and can paradoxically increase A1c levels independently of glucose. Animal and human studies have demonstrated that iron-restricted erythropoiesis produces RBCs with altered membrane permeability and increased glycation susceptibility, leading to a false elevation of A1c. Conversely, iron supplementation during treatment of anemia can rapidly lower A1c as new, healthier RBCs enter circulation. This bi-directional effect complicates serial comparisons and creates a double trap: anemic women with GDM may show falsely elevated A1c and be over-treated, while women with adequate iron stores may show falsely low values and be undertreated. Clinicians must account for iron status whenever interpreting A1c in pregnancy.

4. Changes in Hemoglobin Variants and Fetal Hemoglobin

Pregnancy can induce a mild increase in fetal hemoglobin (HbF) in the mother, and many women carry traits for hemoglobinopathies such as HbS, HbC, or HbE. Some A1c assays (especially older methods) are sensitive to these variants and can produce spurious results. Although modern high-performance liquid chromatography (HPLC) and immunoassays are less affected, interference persists in certain populations. Laboratories must report whether a method is affected by common variants. Women with sickle cell trait, for example, may have A1c readings that are 0.3–0.7% lower or higher depending on the assay chemistry, creating further diagnostic confusion.

5. Hormonal Shifts and Glycemic Variability

Placental hormones—human placental lactogen, growth hormone, cortisol, and progesterone—induce progressive insulin resistance, particularly after 20 weeks. Despite this rise in postprandial glucose, fasting glucose often falls due to increased hepatic glucose uptake and enhanced insulin clearance. The overall glycemic profile becomes more volatile, with rapid swings that a time-weighted average like A1c cannot capture. Even a "normal" A1c may mask dangerous hyperglycemic excursions. Studies using continuous glucose monitoring have shown that pregnant women with GDM can experience postprandial spikes above 180 mg/dL for hours each day while maintaining a deceptively normal A1c below 5.7%.

Specific Limitations of A1c Testing During Pregnancy

The cumulative effect of these changes is a test whose interpretation becomes highly unreliable in the gravid state. Several key limitations deserve emphasis for any clinician managing diabetes in pregnancy:

  • Poor correlation with actual glucose levels: Studies comparing A1c to continuous glucose monitoring (CGM) or oral glucose tolerance tests (OGTT) show correlation coefficients as low as 0.3–0.5 in pregnant women, versus 0.7–0.9 in non-pregnant adults. This means A1c explains as little as 9% of the variance in actual glycemic exposure.
  • False negatives for hyperglycemia: Because A1c is artifactually lowered by dilution and reduced RBC lifespan, many women with GDM will have A1c values below the non-pregnancy diagnostic threshold. Relying solely on A1c would miss up to 40–60% of GDM cases, delaying crucial therapy.
  • False positives in anemic women: As noted, iron deficiency can inflate A1c, leading to unnecessary treatment and added anxiety. Some studies report that correcting iron deficiency can lower A1c by 0.5–1.0% without any change in actual glycemic control.
  • No validated pregnancy-specific cutoffs: Unlike the OGTT, for which large outcome-driven trials have defined pregnancy-specific thresholds (e.g., Carpenter-Coustan criteria), no such established A1c targets exist for diagnosing or treating GDM. Attempts to use A1c alone for screening have yielded inconsistent results, with sensitivity ranging from 20% to 70% depending on the population and cutoff chosen.
  • Inability to detect postprandial spikes: One-hour post-meal glucose peaks are strongly linked to macrosomia and neonatal hypoglycemia, yet they are invisible to A1c. Even if average glucose is normal, dangerous excursions can occur. The landmark Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study demonstrated that these post-load glucose values predict adverse outcomes independently of fasting glucose or A1c.

In recognition of these issues, neither the American College of Obstetricians and Gynecologists (ACOG) nor the ADA recommends A1c for routine GDM screening. When A1c is used during pregnancy (e.g., in pre-existing type 1 or type 2 diabetes), clinicians must apply caution and supplement with self-monitoring. The ADA's Standards of Care explicitly state that "A1c may be lower in pregnancy than in the nonpregnant state due to physiologic changes" and that "the use of A1c alone for diagnosis of diabetes in pregnancy is not recommended."

Alternative and Complementary Monitoring Strategies

Given the unreliability of A1c, clinicians must leverage other tools to maintain glycemic control during pregnancy. The following methods offer advantages in accuracy, timeliness, and clinical actionability.

Self-Monitoring of Blood Glucose (SMBG)

SMBG with finger-stick glucose meters remains the standard for day-to-day management. The typical regimen for GDM includes fasting and one- or two-hour postprandial measurements. Targets recommended by ACOG are fasting ≤95 mg/dL and one-hour postprandial ≤140 mg/dL (or two-hour ≤120 mg/dL). SMBG captures the glycemic pattern that drives pregnancy outcomes, allowing timely insulin dose adjustments. However, compliance can be burdensome, and the data reflect discrete time points rather than the full 24-hour profile. Women who test only four times daily miss approximately 95% of their glycemic data, potentially overlooking significant excursions that occur between measurements.

External resource: ACOG Practice Bulletin on GDM – includes detailed SMBG target recommendations and clinical management algorithms.

Continuous Glucose Monitoring (CGM)

CGM devices measure interstitial glucose every 5–15 minutes, providing a complete picture of glycemic variability, including asymptomatic nocturnal lows and postprandial spikes missed by SMBG. Several randomized trials have shown that CGM in pregnant women with type 1 diabetes improves glycemic control and reduces neonatal outcomes such as large-for-gestational-age infants. For GDM, CGM is increasingly used when SMBG fails to achieve targets or when hypoglycemia is suspected. The landmark CONCEPTT trial demonstrated that CGM use in pregnant women with type 1 diabetes was associated with lower A1c, more time in range, and reduced neonatal complications including fewer large-for-gestational-age births and shorter neonatal intensive care stays.

The latest generation of real-time CGM systems (e.g., Dexcom G6, Abbott Libre 2) do not require finger-stick calibration and offer alarms for high and low glucose. CGM metrics—time in range (TIR, 63–140 mg/dL during pregnancy), time above range (TAR), and time below range (TBR)—provide actionable, intuitive targets. Many experts now propose TIR >70% as a pregnancy-specific goal, with TBR <4% for safety. CGM data can be shared with providers via cloud platforms, enabling remote monitoring and timely interventions.

External resource: ADA CGM in Pregnancy Consensus Report – provides detailed recommendations for CGM use and interpretation during gestation.

Fructosamine and Glycated Albumin

Fructosamine measures glycated serum proteins, primarily albumin, reflecting glycemia over the preceding 2–3 weeks. Because albumin has a half-life of approximately 20 days, fructosamine is less affected by RBC turnover and can reveal changes more rapidly than A1c. In pregnancy, fructosamine correlates moderately well with SMBG averages and is not influenced by iron deficiency or hemoglobin variants. This makes it a particularly valuable tool when A1c is suspect.

Drawbacks include variability with albumin concentration (common in pregnancy due to hemodilution) and the lack of robust outcome-based targets. Nonetheless, fructosamine can serve as a valuable adjunct when A1c is deemed unreliable or when a shorter-term assessment is needed. Some studies suggest a fructosamine target of <265 µmol/L for pregnant women. Fructosamine also responds faster to therapeutic changes, allowing clinicians to assess the impact of insulin adjustments within weeks rather than months.

Glycated albumin (GA) is a newer marker with similar properties but better precision. GA is increasingly available in Asia and parts of Europe but not yet widely adopted in the United States. Both markers require further validation in pregnancy but offer promise as mid-term glycemic indices that can fill the gap between daily SMBG and the flawed A1c.

Oral Glucose Tolerance Testing for Diagnosis

For initial GDM screening and diagnosis, the two-hour 75g OGTT (or the two-step approach with a 50g glucose challenge test) remains the validated gold standard. The OGTT directly measures the body's ability to handle a glucose load after overnight fasting, revealing insulin secretion and resistance. It is performed between 24 and 28 weeks of gestation. Unlike A1c, the OGTT's cutoffs are derived from the Hyperglycemia and Adverse Pregnancy Outcome study, linking each blood glucose level to neonatal outcomes. The HAPO study, which enrolled over 25,000 pregnant women across 15 centers, demonstrated a continuous relationship between OGTT glucose values and adverse outcomes including birth weight >90th percentile, cord-blood C-peptide >90th percentile, and primary cesarean delivery.

External resource: HAPO Study (NEJM) – foundational for GDM diagnostic criteria. This landmark paper established the evidence base for current international GDM diagnostic thresholds.

Practical Recommendations for Clinicians

To navigate the limitations of A1c in pregnancy, clinicians should adopt a multimodal approach that integrates multiple data sources for safe decision-making:

  • Do not use A1c for GDM screening or diagnosis. Follow ACOG/ADA guidelines using the OGTT at 24–28 weeks. A1c is simply not accurate enough for this purpose in pregnancy.
  • In women with pre-existing diabetes (type 1 or type 2), use A1c as a general trend marker but rely on SMBG and/or CGM for daily adjustments. Target A1c <6.5% if possible, but recognize that values 0.3–0.5% lower may reflect the same glycemic burden as in non-pregnancy. Use CGM time-in-range goals as your primary metric for day-to-day management.
  • Monitor for iron deficiency and correct it, especially if using A1c. Check ferritin and iron studies at least once in the second trimester. Re-check A1c after iron repletion to reassess true glycemic status, as correction of anemia can lower A1c by 0.5% or more.
  • Consider fructosamine or GA if A1c is persistently discordant with glucose logs or if hemoglobin variants are present. These tests can provide a more truthful mid-term glycemic picture when RBC physiology is altered.
  • Educate patients about the differences between monitoring methods and the reasons for expanded testing. Help them understand why their A1c alone cannot guide treatment decisions during pregnancy. Empower them to recognize patterns in their glucose data and to trust their SMBG and CGM readings even when they conflict with A1c results.

Future Directions

Research is actively pursuing pregnancy-specific A1c reference equations that account for hematologic changes, as well as risk calculators that incorporate multiple biomarkers. Machine learning models using CGM data may eventually replace A1c for individualized risk prediction, offering personalized glycemic targets based on real-time patterns rather than population averages. Additionally, the integration of CGM with insulin pumps (hybrid closed-loop systems) has shown exceptional outcomes in pregnancy and is likely to become more widespread. The recent AiDAPT trial demonstrated that hybrid closed-loop therapy was safe and effective in pregnant women with type 1 diabetes, improving time in range and reducing hypoglycemia without increasing fetal risks. Until these advanced tools become universally available, clinicians must remain aware that A1c in pregnancy is a flawed tool—not a compass—and that its interpretation demands context, humility, and supplementary data.

Conclusion

Pregnancy transforms the mother's physiology in ways that systematically alter A1c results. Hemodilution, shortened RBC lifespan, iron deficiency, and hormonal shifts combine to make A1c both an unreliable standalone metric and a potential source of clinical error. Relying on A1c alone for GDM management can delay treatment, misclassify risk, or generate false alarms. Instead, obstetric and diabetes care teams should embrace a repertoire of monitoring tools—SMBG, CGM, fructosamine, and the OGTT—to paint an accurate and actionable picture of glucose control. By understanding the limitations of A1c and adapting monitoring strategies accordingly, providers can improve outcomes and reduce the burden of diabetes in pregnancy for millions of women worldwide. The key takeaway is simple: in pregnancy, trust your glucose data, not your A1c alone, and let multimodal monitoring guide your clinical decisions for the safety of both mother and child.